BioStem Raises 2026 Revenue Outlook to $28M–$29M
BioStem reported Q3 2026 revenue of $7.6 million, down from $10.5 million a year earlier, and raised its 2026 revenue outlook to $28 million–$29 million from $26 million–$29 million. Cash was $1.0 million at quarter-end; the company used $8.8 million in operations during the quarter.
BioStem reported Q3 2026 revenue of $7.6M, versus $10.5M a year earlier, and raised 2026 revenue guidance to $28M—$29M from $26M—$29M. Cash was $1.0M at quarter-end, with $8.8M used in operations during the quarter.Material DetailsContext by AI AnalystThe results show a mixed operating picture: ful…